N-Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate structure
|
Common Name | N-Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate | ||
---|---|---|---|---|
CAS Number | 64987-85-5 | Molecular Weight | 334.324 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 501.7±42.0 °C at 760 mmHg | |
Molecular Formula | C16H18N2O6 | Melting Point | 180-182 °C(lit.) | |
MSDS | Chinese USA | Flash Point | 257.2±27.9 °C |
Use of N-Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylateSMCC is a protein crosslinker. SMCC-conjugated antigen coupled spleen cells to induce antigen-specific immune responses[1]. |
Name | succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate |
---|---|
Synonym | More Synonyms |
Description | SMCC is a protein crosslinker. SMCC-conjugated antigen coupled spleen cells to induce antigen-specific immune responses[1]. |
---|---|
Related Catalog | |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 501.7±42.0 °C at 760 mmHg |
Melting Point | 180-182 °C(lit.) |
Molecular Formula | C16H18N2O6 |
Molecular Weight | 334.324 |
Flash Point | 257.2±27.9 °C |
Exact Mass | 334.116486 |
PSA | 101.06000 |
LogP | -0.39 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.598 |
Storage condition | 2-8°C |
Water Solubility | chloroform: 50 mg/mL |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
---|---|
Hazard Codes | Xi: Irritant; |
Risk Phrases | R36/37/38 |
Safety Phrases | S26-S36 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
HS Code | 2925190090 |
~% N-Succinimidyl ... CAS#:64987-85-5 |
Literature: Journal of Pharmaceutical Sciences, , vol. 75, # 7 p. 711 - 713 |
Precursor 1 | |
---|---|
DownStream 0 |
HS Code | 2925190090 |
---|---|
Summary | 2925190090 other imides and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |
A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
J. Immunol. Res. 2015 , 561814, (2015) Antibody-drug conjugates (ADCs) have evolved as a new class of potent cancer therapeutics. We here report on the development of ADCs with specificity for the B-cell lineage specific (surface) antigen ... |
|
Solid formulations by a nanocrystal approach: critical process parameters regarding scale-ability of nanocrystals for tableting applications.
Int. J. Pharm. 485 , 77-86, (2015) Nanocrystallization is among the foremost drug delivery platform approaches for the commercial development of poorly soluble drugs. There exists an urge to enable a universal shift of the production o... |
|
An NIR-triggered and thermally responsive drug delivery platform through DNA/copper sulfide gates.
Nanoscale 7 , 12614-24, (2015) Nanomaterials for effective drug delivery require zero pre-release and on-demand release of therapeutic drugs. In this work we demonstrate a novel drug delivery system composed of a mesoporous silica ... |
MFCD00009634 |
1-[(4-{[(2,5-Dioxopyrrolidin-1-yl)oxy]carbonyl}cyclohexyl)methyl]-1H-pyrrole-2,5-dione |
1H-Pyrrole-2,5-dione, 1-((4-(((2,5-dioxo-1-pyrrolidinyl)oxy)carbonyl)cyclohexyl)methyl)- |
N-Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate |
1-[(4-{[(2,5-Dioxo-1-pyrrolidinyl)oxy]carbonyl}cyclohexyl)methyl]-1H-pyrrole-2,5-dione |
1H-pyrrole-2,5-dione, 1-[[4-[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]cyclohexyl]methyl]- |
N-Succinimidyl 4-(Maleimidomethyl)cyclohexane-1-carboxylate |